Biotech firm files to register $ 50 mil. in convertible subordinated debentures with the Securities and Exchange Commission. Proceeds are expected to be used to support expansion of manufacturing capacity for Xomen-E5 and XomaZyme-H65, development of a marketing and sales force for XomaZyme-H65 and working capital requirements. Dillon Reed, Alex. Brown and Oppenheimer are the underwriters.
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.